Physician profile
Khurram Wadud
NPI 1801877576
$76,937.05
in general payments reported to CMS, 2019-2025
55 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $12K · 2021: $17K · 2022: $19K · 2023: $3,598 · 2024: $2,938 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,645 · Education: $32.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,645.42 |
| Education | $32.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28,605.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $27,290.11 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $4,173.50 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $1,960.27 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $1,393.50 | 2019-2025 | |
| Insulet Corporation | $1,336.04 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $1,288.40 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic Minimed, INC. | $1,169.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $966.13 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $931.73 | 2020-2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $715.14 | 2020-2025 | Unithroid |
| Mannkind Corporation | $660.19 | 2019-2024 | Afrezza |
| Amgen INC. | $645.41 | 2019-2025 | Tepezza, Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $636.29 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Horizon Therapeutics Plc | $575.02 | 2020-2022 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $547.06 | 2019-2025 | |
| Corcept Therapeutics | $401.16 | 2020-2025 | Korlym |
| Antares Pharma, INC. | $398.91 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $374.85 | 2019-2025 | Synthroid |
| Ibsa Pharma INC. | $345.56 | 2019-2025 | Tirosint, Tirosint, Licart |
| Medtronic, INC. | $329.09 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Cequr Corporation | $253.50 | 2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $222.59 | 2025 | Twiist |
| Alexion Pharmaceuticals, INC. | $194.63 | 2022-2025 | Strensiq |
| Endo Pharmaceuticals INC. | $183.42 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $182.01 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $135.05 | 2019-2023 | Verquvo |
| Astellas Pharma US INC | $128.65 | 2023-2025 | Veozah, Myrbetriq |
| Ascensia Diabetes Care US INC. | $107.04 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $81.38 | 2025 | |
| Valeritas, INC. | $79.31 | 2019 | |
| Beta Bionics, INC. | $52.45 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Azurity Pharmaceuticals, INC. | $46.51 | 2023 | Adthyza |
| Lifescan, INC. | $43.10 | 2021-2022 | |
| Acella Pharmaceuticals, LLC | $41.63 | 2022-2023 | NP Thyroid 60 |
| Boston Scientific Corporation | $37.27 | 2021-2024 | |
| Halozyme INC | $34.55 | 2023 | |
| Novartis Pharmaceuticals Corporation | $32.57 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $30.31 | 2025 | Imcivree |
| Madrigal Pharmaceuticals | $30.01 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $28.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.82 | 2019 | |
| Shire North American Group INC | $26.81 | 2019 | |
| Globus Medical, INC. | $25.57 | 2025 | Senza |
| Zealand Pharma US, INC. | $24.54 | 2021 | |
| Grt US Holding, INC. | $24.38 | 2021 | |
| Recordati_rare_diseases_inc. | $23.38 | 2025 | Isturisa |
| Senseonics, Incorporated | $21.00 | 2020 | |
| Glaxosmithkline, LLC. | $19.34 | 2025 | Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $16.72 | 2022 | |
| Kyowa Kirin, INC. | $14.40 | 2024 | Crysvita |
| Ipsen Biopharmaceuticals, INC | $13.62 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.54 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khurram Wadud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.